dr hab. Katarzyna Kuter-Nowak
Strona główna
/
Instytut
/
Pracownicy
/
dr hab. Katarzyna Kuter-Nowak

dr hab. Katarzyna Kuter-Nowak
Dokonania naukowe
- Publikacje
Increased energetic demand supported by mitochondrial electron transfer chain and astrocyte assistance is essential to maintain the compensatory ability of the dopaminergic neurons in an animal model of early Parkinson's disease.
Autorzy:
DOI: 10.1016/j.mito.2018.12.002
Date: 2018-12-20
Prolonged Dysfunction of Astrocytes and Activation of Microglia Accelerate Degeneration of Dopaminergic Neurons in the Rat Substantia Nigra and Block Compensation of Early Motor Dysfunction Induced by 6-OHDA
Autorzy: Katarzyna Kuter, Łukasz Olech, Urszula Głowacka
DOI: 10.1007/s12035-017-0529-z
Date: 2018-04-02
Antidepressant activity of zinc: Further evidence for the involvement of the serotonergic system
Autorzy: Szewczyk, B., Kotarska, K., Siwek, A., Olech, Ł., Kuter, K.
DOI: 10.1016/j.pharep.2017.01.008
Date: 2017-01-01
Adaptation within mitochondrial oxidative phosphorylation supercomplexes and membrane viscosity during degeneration of dopaminergic neurons in an animal model of early Parkinson's disease.
Autorzy: Kuter K, Kratochwil M, Berghauzen-Maciejewska K, Głowacka U, Sugawa MD, Ossowska K, Dencher NA
DOI: 10.1016/j.bbadis.2016.01.022
Date: 2016-04-01
Native DIGE proteomic analysis of mitochondria from substantia nigra and striatum during neuronal degeneration and its compensation in an animal model of early Parkinson’s disease
Autorzy: Kuter, K., Kratochwil, M., Marx, S.-H., Hartwig, S., Lehr, S., Sugawa, M.D., Dencher, N.A.
DOI: 10.1080/13813455.2016.1197948
Date: 2016-01-01
Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats.
Autorzy: Berghauzen-Maciejewska K, Wardas J, Kosmowska B, Głowacka U, Kuter K, Ossowska K
DOI: 10.1371/journal.pone.0117698
Date: 2015-01-01
Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson's disease.
Autorzy: Konieczny J, Jantas D, Lenda T, Domin H, Czarnecka A, Kuter K, Śmiałowska M, Lasoń W, Lorenc-Koci E
DOI: 10.1007/s12640-014-9477-9
Date: 2014-10-01
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Autorzy: Berghauzen-Maciejewska K, Kuter K, Kolasiewicz W, Głowacka U, Dziubina A, Ossowska K, Wardas J
DOI: 10.1016/j.bbr.2014.06.029
Date: 2014-09-01
Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats.
Autorzy: Ossowska K, Wardas J, Berghauzen-Maciejewska K, Głowacka U, Kuter K, Pilc A, Zorn SH, Doller D
DOI: 10.1016/j.neuropharm.2014.03.018
Date: 2014-08-01
Neonatal DSP-4 treatment modifies antinociceptive effects of the CB1 receptor agonist methanandamide in adult rats.
Autorzy: Korossy-Mruk E, Kuter K, Nowak P, Szkilnik R, Rykaczewska-Czerwinska M, Kostrzewa RM, Brus R
DOI: 10.1007/s12640-012-9323-x
Date: 2013-01-01